Valuation: Biogen Inc.

Market Cap 37.61B 58,189B 33.48B 30.71B 27.91B 52.55B 3,559B 53.71B 366B 147B 1,882B 141B 138B 5,958B P/E 2026 *
47.6x
P/E 2027 * 22.9x
Enterprise Value 43.25B 66,906B 38.5B 35.31B 32.1B 60.42B 4,093B 61.75B 420B 169B 2,164B 162B 159B 6,850B EV / Sales 2026 *
4.11x
EV / Sales 2027 * 3.78x
Free-Float
85.81%
Yield 2026 *
-
Yield 2027 * -
1 day+2.69%
1 week+2.50%
Current month+1.17%
1 month+19.68%
3 months+33.93%
6 months+50.50%
Current year+58.34%
1 week 31,640
Extreme 31640
33,100
1 month 26,800
Extreme 26800
33,100
Current year 18,640
Extreme 18640
33,100
1 year 17,200
Extreme 17200
33,100
3 years 9,930
Extreme 9930
33,100
5 years 2,789.5
Extreme 2789.5
33,100
10 years 737
Extreme 737
33,100
Manager TitleAgeSince
Chief Executive Officer 66 13/11/2022
Director of Finance/CFO 60 28/02/2025
Chief Tech/Sci/R&D Officer - 27/10/2024
Director TitleAgeSince
Director/Board Member 69 22/03/2010
Director/Board Member 77 31/12/2009
Director/Board Member 72 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.69%+2.50% - - 36.8B
+0.61%+10.62%+58.16%+149.73% 1,255B
+3.81%+2.82%+48.35%+82.58% 641B
+3.09%+2.95%+39.10%+108.48% 505B
+1.25%-0.78%+52.56%+66.87% 381B
+3.93%+6.02%+82.28%+45.44% 357B
+2.10%+4.26%+34.93%+61.10% 303B
+1.92%+9.37%+13.43%+36.55% 286B
+3.73%+6.82%+61.48%+77.31% 249B
+4.19%+9.68%+42.96%+113.85% 208B
Average +1.88%+2.95%+48.14%+82.43% 465.02B
Weighted average by Cap. +1.15%+3.90%+50.61%+97.79%

Financials

2026 *2027 *
Net sales 10.53B 16,289B 9.37B 8.6B 7.81B 14.71B 996B 15.03B 102B 41.13B 527B 39.52B 38.67B 1,668B 10.76B 16,651B 9.58B 8.79B 7.99B 15.04B 1,019B 15.37B 105B 42.04B 538B 40.4B 39.53B 1,705B
Net income 788M 1,219B 701M 643M 585M 1.1B 74.57B 1.13B 7.66B 3.08B 39.42B 2.96B 2.89B 125B 1.79B 2,764B 1.59B 1.46B 1.33B 2.5B 169B 2.55B 17.37B 6.98B 89.38B 6.7B 6.56B 283B
Net Debt 5.63B 8,716B 5.02B 4.6B 4.18B 7.87B 533B 8.05B 54.77B 22.01B 282B 21.15B 20.69B 892B 3.08B 4,766B 2.74B 2.52B 2.29B 4.3B 292B 4.4B 29.95B 12.03B 154B 11.56B 11.32B 488B
Projected Income Statement - Annual - Biogen Inc.
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
04/11/26 ARS 32,840.00 +2.69% 383
03/11/26 ARS 31,980.00 +0.95% 173
02/11/26 ARS 31,680.00 -2.40% 301
30/10/26 ARS 32,460.00 +2.40% 1,842
29/10/26 ARS 31,700.00 +1.67% 828
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Biogen Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
36
Last Close Price
254.63USD
Average target price
264.82USD
Spread / Average Target
+4.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biogen Inc.